



**Health Protection Agency**

# **Meningococcal Reference Unit**

*Part of HPA Respiratory and Systemic Infections Department (RSID)*



## **User Manual**

**April 2010**

**Contains Information on References Services for:**

- *Neisseria meningitidis* isolate characterisation
- Polysaccharide antigen detection
- *Neisseria meningitidis* (Meningococcal) DNA detection by PCR  
(*Streptococcus pneumoniae* detection by PCR)
- Vaccine response – (pre- and post- immunisation)

Postal address                      Meningococcal Reference Unit  
   Manchester Medical Microbiology Partnership  
   PO Box 209  
   Clinical Sciences Building 2  
   Manchester Royal Infirmary,  
   Oxford Road  
   Manchester, UK M13 9WZ

Hays address:                      DX 6962410  
   Manchester 90 M

Telephone                          #44(0)161 276 6757  
Fax                                      #44(0)161 276 5744  
Out-of-hours Telephone        #44(0)161 276 1234  
   and ask for Medical Microbiologist on-call

Authorised By:


Dr E B Kaczmarek (Head of Unit)

Effective Date: April 2010

# CONTENTS

Introduction.....	4
MRU Contact Details.....	5
Summary of Services and Resources .....	6
Services Available .....	7
Key Factors affecting specimen performance .....	17
MRU Price List .....	18
Specimen & Sample Submission Guidelines.....	19
Faxing and emailing reports containing patient's data.....	22
Compliance with the Human Tissue Act.....	23
MRU Recognition of Caldicott Recommendations.....	23
Key References.....	24
Charity and Public Information Contact Details .....	25
MRU Request Form.....	26

# Meningococcal Reference Unit Introduction



The HPA Meningococcal Reference Unit (MRU) for England and Wales has been situated in Manchester since 1978. Originally established to provide phenotypic characterisation of meningococci isolated in laboratories throughout the country, the nature and scope of this activity has widened as has the range of tests available.

The MRU re-located from Withington Hospital, Manchester to Manchester Royal Infirmary (MRI) in March 2003 as an integral part of the Manchester Medical Microbiology Partnership (MMMP).

The MRU is part of the Respiratory and Systemic Infections Department (RSID) and works closely with other parts of the HPA particularly the Immunisation Division and many other HPA colleagues in LARS to optimise meningococcal disease ascertainment through enhanced surveillance.

The MRU has been a world leader in developing and making nationally available tests for non-culture case confirmation of meningococcal infection by PCR. Initially designed to identify the major disease causing serogroups (A, B, C, Y and W135), the test repertoire has been extended to provide more detailed additional characterisation utilising state of the art molecular techniques including DNA sequencing of genomic material from isolates and directly from clinical specimens where possible.

The optimised surveillance, along with serological studies performed in the HPA Vaccine Evaluation Unit co-located within the MMMP at MRI were key elements in supporting and monitoring the successful introduction of meningococcal serogroup C conjugate vaccine in the UK and have contributed significantly to establishing the international reputation of the MRU.

In addition to providing confirmatory laboratory services, staff from the MRU advise on investigation and management of individual cases and outbreaks.

The MRU and CfI have been active in the recent establishment of a network of national and regional reference laboratories which are collaborating to harmonise and optimise surveillance throughout Europe and sharing this experience with other interested groups in the Americas and Oceania. This has resulted in the establishment of the European Meningococcal Disease Society (EMGM).

# MRU Contact Details

General MRU Result enquiries	
<p>Identification, phenotypic characterisation (serogroup, serotyping, subtyping), molecular characterisation (<i>porA</i> sequencing) and susceptibility testing of isolates</p> <p>Antigen detection</p> <p>PCR</p> <p>Requests for molecular epidemiology</p>	<p><b>Initial contact for most MRU enquiries:</b> <b>Tel 0161 276 6757</b></p> <p><b>Dr Stephen J Gray</b> <b>BMS3</b> Tel: #44(0)161 276 6757 <a href="mailto:steve.gray@hpa.org.uk">steve.gray@hpa.org.uk</a></p> <p><b>Mr Anthony Carr, BMS2</b> <a href="mailto:tony.carr@hpa.org.uk">tony.carr@hpa.org.uk</a></p> <p><b>Mrs Lynne Newbold, BMS2</b> <a href="mailto:lynne.newbold@hpa.org.uk">lynne.newbold@hpa.org.uk</a></p>
Medical Enquiries	
<p>Patient investigation and clinical advice</p> <p>Interpretation of results</p> <p>Outbreak investigation and management advice</p>	<p><b>Dr Edward B Kaczmarek</b> <b>Head of MRU</b> Tel: #44(0)161276 5699 Mobile: 07774243886 <a href="mailto:ed.kaczmarek@hpa.org.uk">ed.kaczmarek@hpa.org.uk</a></p>
Other Key Staff	
<p>Vaccine evaluation, research and development</p> <p>Vaccine response assessment</p> <p>Proposed research projects</p>	<p><b>Professor Ray Borrow</b> <b>Deputy Unit Head of MRU</b> <b>Head of Vaccine Evaluation Unit (VEU)</b> Tel: #44(0)161 276 6793 <a href="mailto:ray.borrow@hpa.org.uk">ray.borrow@hpa.org.uk</a></p>
<p>PCR diagnosis of <i>N. meningitidis</i></p> <p>Service and molecular research projects</p>	<p><b>Dr Malcolm Guiver</b> <b>Head of Molecular Diagnostics</b> Tel: #44(0)161 276 8833 <a href="mailto:malcolm.guiver@hpa.org.uk">malcolm.guiver@hpa.org.uk</a></p> <p><b>Mr John Marsh</b> <b>Deputy Lead BMS</b> Tel: #44(0)161 276 5685 <a href="mailto:john.marsh@cmft.nhs.uk">john.marsh@cmft.nhs.uk</a></p>
<p>Database management</p>	<p><b>Mr Richard Mallard</b> <b>Head of Laboratory Operations HPA North West</b> Tel: #44(0)161 276 5747 <a href="mailto:richard.mallard@hpa.org.uk">richard.mallard@hpa.org.uk</a></p>
Other Sources of Advice	
<p><b>Dr Mary Ramsay Consultant Epidemiologist</b> Immunisation, Hepatitis and Blood Safety Department HPA Centre for Infections 61 Colindale Avenue, London, NW9 5EQ Tel: #44(0)20 8200 6868 E-mail: <a href="mailto:mary.ramsay@hpa.org.uk">mary.ramsay@hpa.org.uk</a></p>	<p><b>Dr Rob George, Director</b> Respiratory and Systemic Infection Laboratory HPA Centre of Infections 61 Colindale Avenue, London NW9 5EQ, Telephone: #44(0)20 8327 7222 Email: <a href="mailto:robert.george@hpa.org.uk">robert.george@hpa.org.uk</a></p>

# Summary of Services and Resources

- Clinical advice for case and outbreak investigation and management
- Meningococcal isolate confirmation and characterisation
- Meningococcal DNA detection by PCR for non-culture case confirmation
- Molecular characterisation of meningococcal isolates and non-culture (DNA positive only) material
- Technical laboratory advice and support for large scale investigations
- Meningococcal vaccine evaluation
- Determination of response to meningococcal vaccination
- Collection of >50,000 phenotypically characterised meningococcal isolates
- Computerised database of laboratory confirmed cases
- Collection of sera from laboratory proven cases of meningococcal disease
- Support for collaborative scientific projects and audits

# Services Available

## Routine Investigations

### *Neisseria meningitidis* isolate characterisation

#### Species confirmation

Phenotypic confirmation of *Neisseria meningitidis* isolates based on morphology and biochemical reactions.

#### Epidemiological characterisation of strains

##### Phenotype:

- (a) **Serogroup:** identification of capsular polysaccharide antigens by serological reactions: coagglutination using polyclonal antibodies (in-house), commercial slide agglutination, commercial latex antigen kits or monoclonal antibodies.
- (b) **Serotype:** identification of class 2/3 (PorB) outer membrane protein by a dot-blot ELISA using monoclonal antibodies.
- (c) **Sero-subtype:** identification of class 1 (PorA) outer membrane protein by a dot-blot ELISA using monoclonal antibodies (supplied by HPA NIBSC)

##### Genotype:

- (a) **Serogroup:** use of PCR based serogroup confirmation enables identification of non-viable organisms.
- (b) **porA - Serosubtype** – genetic characterisation of serosubtype by DNA sequencing. (Routinely tested and reported on all clinical isolates since October 2007).
- (c) **Multi Locus Sequence Typing (MLST):** performed and reported on strains collected for epidemiological investigation.

### Molecular subtyping of isolates

Molecular characterisation of other potential typing targets such as *fetA* and fHbp a component of newly developed vaccines undergoing evaluation.

## **Antibiotic susceptibility testing**

### **Minimum Inhibitory concentrations (MICs):**

The MICs routinely determined on submitted isolates are: penicillin, cefotaxime, rifampicin, ciprofloxacin and sulphonamide (sulphamethoxazole) using Etest (Biomérieux) gradient diffusion methodology.

Other antibiotic susceptibility tests may be performed on request.

## **How to obtain MRU services**

### **Telephone contact**

#### **For general enquiries: 0161 276 6757**

The MRU laboratory is available Monday – Friday, 09:00 to 17:00 (often 08:30 – 17:30 dependent on staffing arrangements)

If your call to the laboratory is not answered promptly, please telephone 0161 276 6757 as staff may be unable to stop a procedure or could be working in one of several other areas.

### **Weekend enquiries**

For urgent clinical enquiries, particularly those occurring out of hours, weekends or on bank holidays please contact Dr Ed Kaczmarek on mobile contact available via the consultant medical microbiologist rota through Manchester Royal Infirmary switchboard 0161 276 1234.

## **Out of hours specimens**

Specimens for PCR investigation must be received at the MRU by 10.00am weekdays to be tested the same working day.

Arrangements to accept couriered urgent samples for PCR or other investigations **must** be agreed with the MRU **before** the samples are sent. Failure to do so may result in the specimen(s) not being tested in a timely fashion.

**Urgent couriered specimens** should be addressed to

**“Microbiologist On-call”** (*if out –of hours*)

**Meningococcal Reference Unit – URGENT SPECIMEN  
Manchester Medical Microbiology Partnership  
Clinical Sciences Building 2  
Manchester Royal Infirmary  
Oxford Road  
Manchester M13 9WL**

If arriving after 5.30pm, Monday – Friday, at weekends, or on Bank Holidays, they should be left at the Manchester Royal Infirmary Accident and Emergency Department in the “On-Call Virology” box.

### **Transport containers and documentation**

It is the responsibility of senders to comply with the current transport legislation and safety recommendations.

Refer to [http://www.dft.gov.uk/426155/425453/800\\_300/infectioussubstances.pdf](http://www.dft.gov.uk/426155/425453/800_300/infectioussubstances.pdf) for current guidelines.

### **Complaints**

Should it be necessary to submit a formal complaint to the MRU about our service please contact either Dr Ed Kaczmarek or Dr Steve Gray.

## **Turnaround times for isolate characterisation**

Optimal turnaround times are conditional on receiving established pure cultures with appropriate documentation

**Serogroup** results for clinical isolates will be telephoned to the sending laboratory as soon as available – usually later on the day of receipt (Monday to Friday). The telephone report is logged but not printed.

A ‘**final report**’ comprising the serogroup, and phenotypic characterisation (serotyping and serosubtyping) and antibiotic MIC profile are reported within 7 working days.

Contact the MRU for urgent weekend reporting or if more rapid results are required e.g. for cluster investigation.

The determination of molecular subtyping (*porA* sequencing variable regions VR1, VR2 and VR3) is reported when available (7 – 10 days) usually as an ‘**additional report**’.

## **Urgent culture specimens**

In circumstances where urgent characterisation of an isolate is required, a provisional serogroup result can be available within two hours of receipt of an established culture.

When additional information of epidemiological importance such as serotyping and serosubtyping is needed rapidly, a provisional phenotypic result can be available later the same working day if isolates are received before 10.00am, Monday to Friday.

Arrangements to expedite urgent specimens should be made by telephone request to the MRU. This is particularly important if samples are likely to arrive at the MRU later than 17:00 Monday – Friday.

Molecular subtyping (*porA* sequencing) requires a minimum of 3 working days from receipt.

## Meningococcal DNA detection by PCR

The MRU uses real-time PCR (ABI Taqman™) assays to confirm *N. meningitidis* (meningococcal disease) and determine the infecting serogroup where possible<sup>1,2,3</sup>.

The MRU meningococcal (*ctrA*) screening assay is performed as part of a duplex assay combined with a pneumolysin PCR for *Streptococcus pneumoniae* detection.

**Note:** The HPA MRU meningococcal PCR assay is a HPA reference service for England and Wales, and when performed at the MRU, is free of charge.

The pneumolysin PCR is also performed free of charge as part of the enhanced surveillance of pneumococcal disease post pneumococcal conjugate (Prevenar) vaccine introduction. Pneumolysin PCR positive samples are currently confirmed as *Str pneumoniae* by an additional autolysin PCR assay.

As part of the enhanced surveillance, pneumococcal DNA positive empyema fluids from patients under 16 years are referred to Cfl for serotyping.

### What specimens to send for Meningococcal PCR

MRU meningococcal PCR assays have been validated on **EDTA (whole blood), CSF, coagulated whole blood, serum, plasma and joint fluids**.

EDTA whole blood and CSF are the preferred specimens.

Plasma or serum can be examined although sensitivity may be compromised

If coagulated bloods are submitted it is only possible to test the serum fraction.

**EDTA blood** (2.5 – 5 mL) sample collected on admission should be sent routinely to the MRU in the event that PCR confirmation is required. Smaller volumes (0.5 – 1 mL) from infants and babies can also be examined.

Heparinised or citrated samples can be tested, but EDTA is preferred

**CSF** samples, if available, should be sent in addition to an EDTA blood sample. Definitive laboratory confirmation of meningococcal meningitis can only be made by analysis of a CSF sample.

Other specimens from normally sterile sites may be examined after prior consultation with the MRU and a blood and/or CSF specimen should accompany them if available.

The nucleic acid extraction processes are designed for fluid samples so there will be limited experience for unusual sample types. Positive results may be determined for such samples on the understanding that these should be considered “unvalidated” particularly with regards to negative results.

Enhanced surveillance of pneumococcal disease has included the successful screening of **empyema fluid** and other respiratory samples by pneumolysin PCR.

If **tissue samples** (or blocks) require examination they should only be submitted following specific consultation with MRU staff. They are not currently considered a routine investigation as they require expert manual processing with concomitant increases in turnaround time.

### **Minimum volumes for PCR testing (DNA extraction):**

**Blood or fluids** - the routine use of automated nucleic acid extraction systems requires a minimum 400 µL of blood but a larger volume is preferred in case repeat testing is required.

If smaller samples are submitted the fluid volume should be at least 100 µL. Small volumes require specific extraction and this will increase turnaround times.

**CSF** - 400 µL or more is preferred but small samples (50 µL) can be tested. The small volumes require specific extraction and will likely increase turnaround times. Low volume CSFs must be submitted in an appropriate sized container or tube. Whole CSF (i.e. an uncentrifuged specimen) should be sent in small sterile containers such as a sterile 2mL screw capped vial (rather than universal containers).

Submission of minimum volumes is not preferred as repeat extraction is required to confirm positivity or the addition of molecular epidemiology assays.

Original CSF (uncentrifuged) or re-suspended CSF deposits are preferred to CSF supernatants in order to increase sensitivity of detection.

### **Collection and timing of samples for PCR testing:**

The likelihood of a positive PCR result decreases as the interval of sampling after starting antibiotics lengthens. Samples for PCR taken more than 48 hours after commencement of antibiotic therapy are unlikely to give useful results. CSF may remain “positive” for longer periods.

Any specimens for PCR tests should be stored at 4°C and **not** frozen prior to transport. Freeze-thawing may reduce the likelihood of positivity with low genome copy samples and can result in cracked or broken containers.

# MRU PCR investigations performed

## Meningococcal PCR investigations

All suitable submitted samples will be tested in a *N. meningitidis* specific (*ctrA*) screening PCR test.

All reactive specimens will then be tested by the serogroup specific PCR assays (based on *siaD*) which detect and distinguish serogroups B, C, Y and W135 strains of *N. meningitidis*. Testing for serogroup A can be performed where indicated using the *mynA* assay.

## Pneumococcal PCRs

The MRU meningococcal (*ctrA*) screening assay is performed as part of a duplex assay with a pneumolysin PCR for *Streptococcus pneumoniae* detection using ABI Taqman™ primers and probes.

The pneumolysin PCR is also free of charge as part of the enhanced surveillance of pneumococcal disease post pneumococcal conjugate (Prevenar) vaccine introduction. Pneumolysin PCR positive samples are currently confirmed as *Str pneumoniae* following an additional and separate autolysin PCR.

## Hib PCRs

An additional and separate PCR assay to detect *Haemophilus influenzae* type b is available on request.

## Other molecular detection assays

Situated within the MMMP molecular diagnostics department the MRU is able to request a variety of additional PCR-based assays including viral causes of meningitis (eg., Herpes simplex, enterovirus). The additional assays are not part of the free meningococcal service but may be added to requests at the time of submission or later. Should only limited amounts of unrepeatable samples be available this may be a cost-effective option. Nucleic acid extracts containing both DNA and RNA are available for rapid testing.

Additional viral PCRs will be invoiced.

If the additional viral PCRs are not stated on the request form it is necessary to provide the requesting clinician's name at the time of the telephone request.

## Availability of results

Results on specimens received up to 10.00 on Monday – Friday are normally available between 16:30 and 17:00 on the same day.

Positive results will be telephoned following serogroup confirmation up to 17:30pm or as soon as possible on the morning of the next working day when printed reports will also be sent out. It is useful to telephone the MRU where a result is of great urgency.

**NB:** Although copy results are possible for the HPU it is the responsibility of the requesting laboratory to inform their local CCDC (HPU) of positive meningococcal PCR results in an appropriate timely fashion.

### Urgent PCR specimens

These should be discussed with a member of the MRU staff, (who will liaise with colleagues performing the assays) and make arrangements for the earliest possible testing. Contact details will be required, especially any out-of-hours contact at the sending laboratory, relevant CCDC or HPU.

**Do not** send urgent samples that will arrive out of hours without first discussing with MRU staff. Refer to 'out of hours' section on page 8.

## **Antigen detection - non-culture confirmation**

### **Polysaccharide antigen detection**

Meningococcal antigen detection using commercial latex agglutination kits is available on request. Please discuss with a member of MRU staff before the sample is submitted.

For acute investigations, PCR is preferred as it is more sensitive and if positive, additional molecular typing can be performed.

**NB:** Antigen detection will reduce material available for PCR and could compromise the integrity of the sample.

### **What specimens to send for polysaccharide antigen detection:**

CSF and serum – a minimum sample volume of 200µL is preferred.

### **Turnaround time**

Telephone reports are available on day of receipt.

Printed reports normally sent out on the following working day.

### **Urgent specimen**

These can be processed and results telephoned within two hours of receipt at the MRU. Please discuss with the MRU if urgent antigen tests are required.

# Meningococcal Serology

## (a) Serodiagnosis

Serodiagnosis of meningococcal disease is not routinely available

## (b) Pre- and post vaccine response

The following services are available from the HPA Vaccine Evaluation Unit (VEU) based at the MMMP

**Functional, total immunoglobulin and isotype specific antibody levels for immunogenicity studies by internationally standardised assays are available.**

**Samples of clotted blood or serum should be collected three to eight weeks post-vaccination.**

A minimum sample volume of 500µL is preferred.

**There will be a charge for these investigations unless they are part of an MRU or HPA instigated epidemiological investigation.**

1. Quantitation of total IgG to serogroups C, Y, W135 or A polysaccharides.
2. Functional antibody to serogroup C, Y, W135 or A meningococci by internationally standardised serum bactericidal assays (SBAs).
3. Novel assays (bactericidal and ELISA) for other meningococcal serogroups, such as B are available on request.

## Charges

Requests for vaccine response testing, if not initiated as part of an MRU or HPA epidemiological or case investigation, will be charged for.

## Turnaround Times

Serogroup C vaccine response results are available within 28 working days of submission.

# Key factors affecting specimen performance

## What specimens to send

**All** submitted samples must comply with the sample acceptance policy and be accompanied by a completed MRU request form which can be downloaded from the HPA website.

### Isolates for case confirmation, epidemiology and cluster management:

1. Please submit **all** sterile site (CSF, blood and joint fluids) isolates from cases.
2. If available, please submit throat and nose swab isolates from cases also.
3. Isolates from case contacts (nose or throat swabs)

A complete case sample set could include; CSF, blood, joint fluid, nose and throat isolates. *They are useful for molecular studies and validation of typing techniques.*

### Other non-sterile sites:

1. Invasive respiratory samples (eg BALs), samples obtained by surgical procedure.
2. Respiratory/sputum sample isolates if thought to be clinically significant
3. *N. meningitidis* isolates with high MICs or unusual antibiograms

Note: that approximately 30% of *N. meningitidis* isolates have penicillin MICs > 0.06 mg/L (BSAC breakpoint) and MICs up to 0.38 mg/L are not unusual

Isolates with penicillin MICs > 0.5 mg/L are worth investigating

### GenitoUrinary Medicine (GUM) isolates

1. Please **do not submit** routine GUM isolates

Only submit isolates from GUM patients if they appear resistant (high MICs of  $\geq$  0.25mg/L) or are epidemiologically significant.

### Other Neisseria species

The MRU is established to confirm *N. meningitidis* and determine epidemiological markers.

1. The identification of Neisseria species other than *N. meningitidis*, *N. lactamica* and *N. gonorrhoeae* is problematic.

Please do not submit isolates or organisms that are very unlikely to be *N. meningitidis* or *lactamica*. *N. gonorrhoeae* should be referred to Cfl.

# MRU Price List

## Meningococcal Reference Unit, 2009/2010 price list

	Turn round time for Provisional result (working days)	Turn round time to Final result (working days)
Meningococcal cultures (outside England & Wales, where FOC)	Provisional results are telephoned within 24-72 hours  Printed reports issued within 1-2 weeks	2 weeks
Meningococcal PCR (outside England & Wales, where FOC)	24 hours	48-72 hours
Meningococcal serology - serum bactericidal assay - per target	28 days	28 days
Meningococcal serogroup specific IgG	28 days	28 days

Contact Mr Richard Mallard ([richard.mallard@hpa.org.uk](mailto:richard.mallard@hpa.org.uk)) for details of current prices.

# Specimen and Sample Submission Guidelines

## SPECIMEN ACCEPTANCE POLICY – GUIDANCE FOR LABORATORIES AND HEALTH PROTECTION UNITS

### **LABELLING YOUR SPECIMENS MATTERS**

Specimens **must** be correctly labelled and request forms adequately completed. Don't be the cause of specimen rejection, confusion, delay.....

Please follow the rules:

**Specimens MUST** be labelled with the following:

Surname

Sender reference number

**PLUS** any two out of three of the following:

Forename

Full Date of Birth

NHS Number

**AND** Date of Collection of Specimen

**Request forms MUST** match the information on the sample

**PLUS** Address for the report / requesting laboratory

Patient address with postcode

Consultant, GP, CsCDC

Name of requestor

Tests required

Sender Reference Number

**Request forms SHOULD** have

Time and Date collected

Sex

Contact number for requestor

Relevant clinical information

Postcode

If you have any problems/queries contact: Dr Steve Gray, BMS3, MRU:  
[steve.gray@hpa.org.uk](mailto:steve.gray@hpa.org.uk) Tel: 0161 276 6757 Fax: 0161 276 5744

## Information required

The MRU request form **MUST** be used whenever specimens are submitted.

This can be downloaded from the HPA website.

Completion of the form ensures that the relevant investigations are carried out and reported back to sending laboratories with minimum delay. If important information is missing, sending laboratories may be contacted to supply details before testing is performed. **Please see the MRU specimen acceptance policy on the previous page.**

It would be helpful if all requesting laboratories supplied their **telephone** and **fax** numbers.

The following information is important for accurate patient data reconciliation and assists provision of meaningful local statistics: **date of birth; home post code; health district of residence.**

### Isolates

Please send cultures from **all** positive sites.

For all isolates:

- Presenting clinical features i.e. meningitis, septicaemia, both (if other, please give details).

Where relevant:

- Names of other possibly related cases.
- In contact tracing, the name of the index case and location (school/town etc).
- Recent travel details if there is a possibility of the disease being contracted abroad.

### Meningococcal PCR

- Type of specimen – EDTA / Heparin / Serum/ CSF
- Time elapsed since illness onset
- Whether and when parenteral antibiotics have been given in relation to sample collection

## How to send isolates – transport

**Only submit** viable isolate samples in **approved packaging (UN3373)** which are suitable for Royal Mail post (airfreight) or commercial couriers such as HAYS DX.

**Agar slopes:** where possible pure, viable cultures; inoculated on chocolate (heated) blood agar, blood agar or Dorset egg slopes after establishing growth by overnight incubation at 37°C.

On occasion it may be necessary to submit an unincubated culture. This can save time but requires a heavy inoculum to ensure survival in transport. Please indicate on the request form if the material (slope) has not been incubated.

Short-term storage of sloped cultures is optimal at 30°C if there are delays before submission.

**Non-viable cultures:** cultures which are no longer viable may still be considered for characterisation by molecular based methods after consultation with the MRU. A heavy inoculum of the inert material on a slope may be submitted with an appropriate request form.

## Additional tests

Additional tests can be requested by telephone or letter on samples received by the laboratory up to 2 months after the receipt of the sample, although it must be recognised that the archive sample available may have a limited volume.

# Faxing and emailing reports containing patients' data

The following guidelines are prepared having taken into account the Code of Practice on reporting patients' results by fax prepared by the DoH and Caldicott recommendations.

It is MMMP (MRU) policy that reports containing patients' data, wherever possible, should not be sent by fax or e-mail.

E-mails cannot be relied on to guarantee security of patients' data because they can be intercepted by a third party on route, unless encryption is used.

In exceptional circumstances it may be necessary to send a result by fax but not by e-mail. In this case the following conditions must be adhered to after discussion with the laboratory.

The patient's name must be conveyed separately using a linking patient identifier.

The report must be sent to a "safe-haven" fax machine. This means that, if the location is in general use, consideration must be given to ensuring that unauthorised personnel are unable to read reports, accidentally or otherwise. Also, the room housing the fax machine must be a secure location which is locked if it is likely to be unattended at the time the fax is sent.

Assurance must be sought from the intended recipient of the faxed report, preferably in writing, that the receiving fax machine is a safe-haven.

Measures must be taken to minimise the risk of mis-dialling, either by double-checking numbers or having frequently used numbers available on the fax machine's memory dial facility.

Confirmation must always be sought from the intended recipient that the fax is expected and has been received.

## **Compliance with the Human Tissue Act – submitting samples from deceased people**

The MMMP / MRU adhere to the HTA and its application within the Central Manchester Foundation Trust site.

Tissue samples (CSF, whole blood EDTA, blood, etc.) from patients are submitted to the MRU with their consent (obtained at time of sampling) for disease confirmation, epidemiological or public health investigations. Samples are tested and retained in accordance with the MRU specimen retention policy. Where, original samples (following nucleic acid extraction) are kept frozen for up to one year after receipt should sufficient remain following initial processing.

Since 2006, post mortem samples or samples from the deceased (patients known by the MRU to have died) at the time of submission have been destroyed sensitively (or returned if requested).

A minimal number of highly selected positive samples are retained for quality control, assay development s or epidemiological investigation under the local HTA guidance.

Should it be necessary to contact the MRU regarding an HTA issue, the Person Designated (PD) is Professor Ray Borrow, tel 0161 276 6793.

## **MRU Recognition of Caldicott Recommendations**

The recommendations of the Caldicott Report (1997) have been adopted by the Health Protection agency as by the National Health Service as a whole. These recommendations relate to the security of patient identifying data (PID) and the uses to which they are put. MRU as an integral part of Manchester Medical Microbiology Partnership observes Caldicott guidance in handling PID. The MMMP has appointed its own Caldicott Guardian who advises on confidentiality issues and is responsible for monitoring the physical security of PID. This also applies to the transfer of results of investigations to and from MMMP whether by mail services, telephone or fax. The value of 'safe haven' arrangements or other means of the sender and receiver of information identifying themselves to each other before data are transferred is emphasized.

MMMP is anxious to audit the security of its PID in collaboration with its customers. Customers are invited to review our arrangements in conjunction with the Caldicott Guardian. Customers are also asked to draw to the Caldicott Guardian's attention any instances where PID security has been threatened or has broken down. Uses that PID are put to outside clinical diagnostic services generally allow patient identifiers to have been removed before hand, and when PID is used for research purposes the proposals are considered first by the HPA Research Ethics Committee. All enquiries about the security and use of PID should be addressed to the Caldicott Guardian, Prof F J Bolton (Tel: 0161276 5699; e-mail [eric.bolton@hpa.org.uk](mailto:eric.bolton@hpa.org.uk)).

## Key References

- Kaczmarski EB, Cartwright KAV. Control of meningococcal disease: guidance for microbiologists. *Comm Dis Rep Rev* 1997; **5**: R196-R198.
- Kaczmarski EB. Meningococcal disease in England and Wales: 1995. *Comm Dis Rep Rev* 1997; **7**: R55-R59.
- Guiver M, Borrow R, Marsh J, Gray SJ, Kaczmarski EB, Howells D, Boseley P, Fox AJ. Evaluation of the Applied Biosystems automated Taqman polymerase chain reaction system for the detection of meningococcal DNA. *FEMS Immunol Med Microbiol* 2000; **28**: 173-179.
- Guiver M and Borrow R. (2001) PCR diagnostics. In: *Meningococcal Disease. Methods in Molecular Medicine* (eds. Pollard AJ and Maiden MCJ) pp 23 – 39. Humana Press, Totowa, New Jersey.
- Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, Mallard RH and Kaczmarski EB. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. *J Med Microbiol* 2006; **55**: 887-896
- Gray SJ, Borrow R, Kaczmarski EB. (2001) Meningococcal serology. In: *Meningococcal Disease. Methods in Molecular Medicine* (eds. Pollard AJ and Maiden MCJ) pp 61 – 87.. Humana Press, Totowa New Jersey.
- Borrow R, Carlone GM. (2001) Seogroup B and C serum bactericidal assays. In: *Meningococcal Vaccines. Methods in Molecular Medicine* (eds. Pollard AJ and Maiden MCJ) pp 289 – 308. Humana Press, Totowa, New Jersey.
- Corless CE, Guiver M, Borrow R, Edwards-Jones V, Fox AJ, Kaczmarski EB. Simultaneous detection of *Neisseria meningitidis*, *Haemophilus influenzae*, and *Streptococcus pneumoniae* in suspected cases of meningitis and septicemia using real-time PCR. *J Clin Microbiol.* 2001; **39**:1553-8.
- Cartwright K. Meningococcal Disease. J Wiley & Sons 1995.
- Feavers IM, Fox AJ, Gray SJ, Jones DM and Maiden MC. Antigenic diversity of meningococcal outer membrane protein porA has implications for epidemiological analysis and vaccine design. *Clin. Diagn. Lab. Immunol* 1996; **3**(4): 444-450.
- Jolley K, Urwin R, Suker J, and Gray SJ. 2006. Methods for meningococcal typing in Handbook of Meningococcal Disease: Infection, biology and Clinical Management. Editors M Frosch and MCJ Maiden. Chpt3; 37-51. Wiley-VCH, USA.
- Kuipers, B., van den Dopplesteen, G., Wedege, E. & van Alphen, L. 2001. Serological characterization. In *Meningococcal Disease: methods and protocols*. pp131-145. Edited by Pollard, A.J. & Maiden, M.C.J. Humana Press Inc., Totowa, New Jersey, USA
- Rosenqvist, E., Wedege, E., Hoiby, E.A. & Froholm, L.O. 1990. Serogroup determination of *Neisseria meningitidis* by whole-cell ELISA, dot-blotting and agglutination. *APMIS* 1990; **98**: 501-506.
- Suker J, Feavers IM and Maiden MC. Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: implications for serological typing and vaccine design. *Microbiology* 1996; **142**: 63-69.
- Wedege, E., Hoiby, E.A., Rosenqvist, E. & Froholm, L.O. Serotyping and serosubtyping of *Neisseria meningitidis* isolates by co-agglutination, dot-blotting and ELISA. *J Med Microbiol* 1990; **31**: 195-201.

# Charities and Public Information Contact Details

Meningitis Trust - Head Office  
Fern House  
Bath Road  
STROUD  
Gloucestershire  
GL5 3TJ  
United Kingdom

24 hour free phone helpline: 0800 028 18 28

Tel: +44 (0)1453 768000

Fax: + 44 (0)1453 768001

E-mail: [info@meningitis-trust.org](mailto:info@meningitis-trust.org)

<http://www.meningitis-trust.org>

Meningitis Research Foundation  
Midland Way  
Thornbury  
Bristol  
BS25 2BS

Tel: +44 (0) 01454 281811

Fax: +44 (0) 01454 281094

Email: [info@meningitis.org](mailto:info@meningitis.org)

<http://www.meningitis.org/>

Meningitis UK  
25 Cleeve Wood Road  
Downend  
Bristol  
BS16 2SF

Tel: +44 (0) 0117 373 73 73

Fax: +44 (0) 0117 373 73 74

Email: [information@meningitisUK.org](mailto:information@meningitisUK.org)

Web: [www.meningitisUK.org](http://www.meningitisUK.org)

**Health Protection Agency**  
**Meningococcal Reference Unit**  
 Manchester Medical Microbiology Partnership  
 PO Box 209, Manchester Royal Infirmary  
 Clinical Sciences Building  
 Manchester M13 9WZ UK  
 Tel: +44 (0)161 276 6757 Fax: +44 (0)161 276 5744

**Hays DX:**  
**Meningococcal Reference Unit**  
 HPA North West, Manchester Lab  
 DX 6962410  
 Manchester 90 M



<b>DETAILS OF SENDER</b>	<b>LABORATORY</b> ( <i>Clearly state department, please</i> ):					
	ADDRESS:					
Tel:		Fax:		Out of hours contact no:		
NAME OF CCDC FOR DISTRICT OF PATIENT'S RESIDENCE:						
ADDRESS:						
Tel:		Fax:		Out of hours contact no:		
<b>PATIENT DETAILS</b>	<b>SURNAME:</b>		<b>CONSULTANT:</b>			
	<b>FORENAME:</b>		<b>WARD:</b>			
	<b>DOB:</b>		<b>HOSPITAL:</b>			
	<b>SEX:</b> male / female					
	<b>HOSPITAL NUMBER:</b>					
	<b>HOME ADDRESS:</b>					
	<b>POST CODE</b> ( <i>Essential information</i> ):					
<b>CLINICAL INFORMATION</b>	<b>DATE OF ONSET:</b>	<b>FATAL:</b>	yes / no / nk			
	<b>CLINICAL DETAILS</b>	<b>PATIENT STATUS:</b>	case / carrier / contact			
		<b>RECENT TRAVEL ABROAD:</b>	yes / no / nk			
		<b>COUNTRY:</b>				
		<b>TYPE OF INCIDENT:</b>	sporadic / outbreak			
	<b>ANTIBIOTIC TREATMENT:</b>	<b>CONTACT HISTORY:</b>	family / school / none / nk			
Further information (associated cases, transfers from other hospitals etc):			<b>Previous Meningococcal Vaccination Details</b> (A C Poly, C Conj, Other – with dates)			
Details of ALL isolates of <i>N. meningitidis</i> including site (CSF, blood, throat, other):						
<b>SPECIMEN DETAILS</b>	Test required	Nature of specimen <i>Please send all meningococci isolated stating site</i>	Senders reference	Date of collection	MRU use only	
	<b><i>N. meningitidis</i></b> Identification, characterisation & sensitivity testing	1.				
		2.				
		3.				
	<b>PCR Meningococcal PCR</b> <input type="checkbox"/>	EDTA Blood				
CSF						
<b>Pneumococcal PCR</b> <input type="checkbox"/>	Serum (clotted blood) or other					
<b>Serology</b> pre- or post vaccine	serum					

April 2010

**PLEASE COMPLETE FULLY TO AVOID DELAYS (REFER TO USER MANUAL)**